In vitro activity and function of B7-H4-Ig fusion protein

Susanne B. Rasmussen, Michael Kosicki, Signe G. Svendsen, Mogens H. Claesson, Nanna N. Kristensen

Laboratory of Experimental Immunology, Department of International Health, Immunology and Microbiology, The Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.

DOI: 10.4236/oji.2013.31004                

Abstract

B7-H4 has been shown to inhibit T cell proliferation, cytokine production and cell cycle in vitro. B7-H4 deficient mice develop exacerbated disease in the mouse models of Rheumatoid Arthritis (RA), Type 1 Diabetes (T1D) and Experimental Autoimmune Encephalomyelitis (EAE). On the other hand, B7-H4-Ig fusion protein has been documented to assuage the symptoms in mouse models of RA, T1D, and multiple sclerosis in vivo. In the present study, B7-H4-Ig bound to the majority of human peripheral blood monocytes and NK cells, but not to either normal or activated T cells. B7-H4-Ig fusion protein was assayed for its effects in allogeneic mixed lymphocyte culture (MLC) systems. Soluble B7- H4-Ig had no significant effect in the MLC, but with a tendency to promote allogeneic response. Immobilized, but not soluble B7-H4-Ig inhibited plastic bound anti-CD3 mediated activation of T cells. This inhibition however was largely due to B7-H4-Ig mediated displacement of anti-CD3 antibody from the plastic plate. Finally, B7-H4-Ig had no effect on the cytotoxicity mediated by NK and LAK cells in PBMC. Our findings thus caution against the interpretation of suppressive effect observed solely in plate-bound anti-CD3 mediated T cell co-stimulation in vitro.

Keywords

CD28 Family; B7-H4; Fusion Protein; MLC

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Prasad, D.V.R., Richards, S., Mai, X.M. and Dong, C. (2003) B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity, 18, 863-873. doi:10.1016/S1074-7613(03)00147-X
[2]	Sica, G.L., Choi, I.H., Zhu, G.F., Tamada, et al. (2003) B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity, 18, 849-861. doi:10.1016/S1074-7613(03)00152-3
[3]	Zang, X., Loke, P., Kim, J., Murphy, K., Waitz, R. and Allison, J.P. (2003) B7x: A widely expressed B7 family member that inhibits T cell activation. Proceedings of the National Academy of Sciences, 100, 10388-10392. doi:10.1073/pnas.1434299100
[4]	Mao, Y.X., Chen, Y.J., Ge, Y., Ma, H.B., et al. (2006) Recombinant human B7-H4 expressed in Escherichia coli inhibits T lymphocyte proliferation and IL-2 secretion in vitro. Acta pharmacologica Sinica, 27, 741-746. doi:10.1111/j.1745-7254.2006.00338.x
[5]	Kryczek, I., Wei, S., Zou, L., Zhu, G., et al. (2006) Cutting edge: Induction of B7-H4 on APCs through IL-10: Novel suppressive mode for regulatory T cells. Journal of Immunology, 177, 40-44.
[6]	Choi, I.H., Zhu, G., Sica, G.L., Strome, S.E., Cheville, J.C., Lau, J.S., Zhu, Y., Flies, D. B., Tamada, K. and Chen, L. (2003) Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. Journal of Immunology, 171, 4650-4654.
[7]	Chinnadurai, R. and Grakoui, A. (2010) B7-H4 mediates inhibition of T cell responses by activated murine hepatic stellate cells. Hepatology, 52, 2177-2185. doi:10.1002/hep.23953
[8]	Chen, Y., Yang, C., Xie, Z., Zou, L., Ruan, Z., Zhang, X., Tang, Y., Fei, L., Jia, Z. and Wu, Y. (2006) Expression of the novel co-stimulatory molecule B7-H4 by renal tubular epithelial cells. Kidney International, 70, 2092-2099.
[9]	Zou, W. and Chen, L. (2008) Inhibitory B7-family molecules in the tumour microenvironment. Nature Reviews, Immunology, 8, 467-477. doi:10.1038/nri2326
[10]	Kryczek I., Zou L., Rodriguez P., Zhu, G. et al. (2006) B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. Journal Experimental Medicine, 203, 871-881. doi:10.1084/jem.20050930
[11]	Azuma T., Zhu G.F., Xu H.Y., Rietz A.C., et al. (2009) Potential Role of Decoy B7-H4 in the Pathogenesis of Rheumatoid Arthritis: A Mouse Model Informed by Clinical Data. Plos Medicine, 6, Article ID: e1000166. doi:10.1371/journal.pmed.1000166
[12]	Wei J., Loke P., Zang X. and Allison J.P. (2011) Tissue-specific expression of B7x protects from CD4 T cell-mediated autoimmunity. Journal Experimental Medicine, 208, 1683-1694. doi:10.1084/jem.20100639
[13]	Wang X. Hao J., Metzger D.L., Mui A., et al. (2011) Early treatment of NOD mice with B7-H4 reduces the incidence of autoimmune diabetes. Diabetes, 60, 3246-3255. doi:10.2337/db11-0375
[14]	Chen L. (2004) Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nature Reviews Immunology, 4, 336-347. doi:10.1038/nri1349
[15]	Geisler C., Plesner T., Pallesen G., Skj?dt et al. (1988) Characterization and expression of the human T cell receptor-T3 complex by monoclonal antibody F101.01. Scandinavian Journal of Immunology, 27, 685-696. doi:10.1111/j.1365-3083.1988.tb02402.x
[16]	Wang X., Hao J., Metzger D.L., Ao Z., et al. (2012) B7-H4 treatment of T cells inhibits ERK, JNK, p38, and AKT Activation. PloS One, 7, Article ID: e28232. doi:10.1371/journal.pone.0028232
[17]	Suh W.K., Wang S., Duncan G.S., Miyazaki Y., Mak, T.W., et al. (2006) Generation and characterization of B7-H4/B7S1/ B7x-deficient mice. Molecular and Cellular Biology, 26, 6403-6411. doi:10.1128/MCB.00755-06